Creating a new drug to treat heart damage after a heart attack
Official title: Developing a new drug for treating myocardial ischemia/reperfusion injury
Funded at Dupage Medical Technology, INC. · NIH-10491205 · Data updated 2026-11-12
This study is testing a new medication that aims to help people who have had a heart attack by reducing heart damage when blood flow is restored, and it could lead to better recovery and lower chances of heart failure.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dupage Medical Technology, INC. NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | September 20, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $1,141,737 |
| NIH project number | 5R44HL156560-02 |
| Project ID | NIH-10491205 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently suffered a myocardial infarction and are at risk of subsequent heart failure.
✕Less likely to help
Patients who have not experienced a heart attack or those with advanced heart failure may not benefit from this research.
What this research studies
This research focuses on developing a new medication aimed at reducing heart damage caused by myocardial ischemia/reperfusion injury, which occurs when blood flow is restored to the heart after a blockage. The approach involves understanding the role of inflammation and microvascular thrombosis in this injury, and how existing anti-platelet drugs can be optimized for better outcomes. Patients who have experienced a heart attack may benefit from this new treatment, which seeks to improve recovery and reduce the risk of heart failure. The research will involve clinical trials to assess the effectiveness and safety of the new drug.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces heart damage and improves recovery for heart attack survivors.
How similar studies have gone: Previous research has shown promise in using anti-platelet therapies for myocardial infarction, but this approach aims to refine and enhance those treatments for better outcomes.
Where this research is happening
-
Dupage Medical Technology, INC.
Chicago, United States Active
Researchers
- Principal investigator: Skidgel, Randal a — Dupage Medical Technology, INC.
- Study coordinator: Skidgel, Randal a
Related research
Other NIH-funded projects on the same topics.
-
Targeting endothelial epsins to help the heart heal after a heart attack
Researchers are studying a protein in blood vessels to find ways to improve blood flow and heart repair after a heart attack.
-
Role of miR98 in heart injury during late pregnancy
A study in pregnant people or models will look at how a tiny molecule called miR98 affects heart injury after a heart attack during the third trimester.
-
Role of LonP1 in protecting the heart from ischemia-reperfusion injury
A study to see if boosting a mitochondrial protein called LonP1 can reduce heart damage after a blocked artery is opened in people who have a heart attack.
-
Helping the heart recover after a heart attack by targeting blood vessel cell proteins (epsins)
This project tests whether blocking a protein called epsins in the cells that line blood vessels can help the heart heal better after a heart attack.
-
How metabolic syndrome harms heart blood vessels
The team is testing whether common diabetes drugs can help blood vessels grow and protect the heart in people with metabolic syndrome and diabetes by studying a pig model that mimics patients.
-
Exploring the use of a protein to improve heart recovery after injury.
This study is looking at how a small protein called ubiquitin might help the heart heal better after it's been damaged from not getting enough blood, like during a heart attack, by reducing inflammation and scarring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.